medwireNews: EULAR has issued updated recommendations for the pharmacologic management of psoriatic arthritis (PsA).
“These recommendations have been modified substantially compared with the 2015 update,” say Laure Gossec (Sorbonne Universite, Paris, France) and co-authors, noting that “new information has accumulated on the efficacy and safety of established drugs and treatment strategies, but also on newer agents” including interleukin (IL)-17 inhibitors, IL-12/23 inhibitors, and Janus kinase inhibitors.
The guidelines are based on both evidence and expert opinion, and comprise six overarching principles addressing the diversity of PsA manifestations, along with 12 recommendations on pharmacologic treatment strategies.
“As before, the recommendations make it clear that one drug does not fit all and stipulate the role of the phenotypes and patient characteristics in the decision-making process of starting and stopping treatments,” write Gossec and team.
The updated recommendations, which are summarized in a treatment algorithm, are published in the Annals of the Rheumatic Diseases.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group